Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Patients Continue To Overpay For Off-Patent Drugs Despite $373bn In Savings

Middlemen Markups Are Costing Patients At The Pharmacy Counter

Executive Summary

The US Association for Accessible Medicines’ annual report into generic and biosimilar savings has documented another year of increased cost savings thanks to off-patent drugs, but says some patients are still overpaying for their generic medicines. 

You may also be interested in...



‘Significant Discounts’ For Biosimilars Could Disrupt US Market

With the launch of rivals to Humira looming in 2023, removing barriers to free pricing and reforming formularies will be essential to promote biosimilar competition in the US, according to Wayne Winegarden of the Pacific Research Institute.

US Patients Increasingly Reliant On Pharmacy Discount Cards For Generics

IQVIA has published a white paper examining the growing reliance on pharmacy discount cards to pay for prescriptions in the US.

‘Middlemen’ Markups Are Penalizing Patients, Says AAM

The Association for Accessible Medicines has launched its Markup Madness campaign, which seeks to draw attention to the disparity in cost between generic drugs upon entry to the supply chain and when purchased in pharmacies.

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB152185

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel